BioCentury | Jan 24, 2018
Emerging Company Profile

D over L for diabetes

...antigens in preclinical through Phase I testing for the disease. At least one other company, Virobay Inc....
...not specific for any one HLA allele, the strategy could lead to overly broad immunosuppression. Virobay...
...Mentioned ImmunoMolecular Therapeutics LLC, Broomfield, Colo. JDRF, New York, N.Y. Tolerion Inc., Portola Valley, Calif. Virobay Inc....
BioCentury | Jul 25, 2017
Distillery Therapeutics

Autoimmune disease

...with vehicle. Next steps could include identifying and testing CTSS inhibitors in models of lupus. Virobay Inc....
...in Phase I testing to treat pain and in discovery research to treat Alzheimer's disease. Virobay...
BioCentury | Aug 18, 2015
Company News

Management tracks

...Palo Alto, Calif.) named James Welch CFO and James Shaffer CBO. Welch was CFO at Virobay Inc....
BioCentury | Nov 10, 2014
Financial News

Virobay withdraws IPO

...Date announced: 2014-10-31 Type: IPO Underwriters: Piper Jaffray; JMP Securities; Cantor Fitzgerald; Summer Street Note: ViroBay...
BioCentury | Nov 1, 2014
Financial News

Virobay pulls IPO

Virobay Inc. (Menlo Park, Calif.) withdrew its proposed IPO on NASDAQ, citing market conditions. Earlier this month, the company amended its offering to sell 3.8 million shares at $12-$14. At $13, it would have raised...
BioCentury | Oct 13, 2014
Financial News

Virobay amends IPO

...IPO on NASDAQ and now plans to sell 3.8 million shares at $12-$14. In September, Virobay...
BioCentury | Oct 7, 2014
Financial News

Virobay, Xenon set IPO terms

...proposed IPOs on NASDAQ Virobay plans to sell 3.8 million shares at $12-$14. At $13, Virobay...
...$169 million. Piper Jaffray; JMP Securities; Cantor Fitzgerald; and Summer Street Research Partners are underwriters. Virobay...
BioCentury | Oct 6, 2014
Finance

4Q14 Financial Markets Preview: 'Perfect world' - for now

...9/15/14 Up to $65M Ph II Kolltan Pharmaceuticals Inc. 9/12/14 Up to $86.3M Ph I Virobay Inc....
BioCentury | Sep 15, 2014
Financial News

Virobay proposes IPO

Virobay Inc. , Menlo Park, Calif. Business: Autoimmune, Neurology, Hepatic Date announced: 2014-09-10 Type: IPO To be raised: Up to $50 million Shares: TBD Price: TBD Underwriters: Piper Jaffray; JMP Securities; Cantor Fitzgerald; Summer Street Note:...
BioCentury | Sep 12, 2014
Financial News

Virobay files for IPO

...on NASDAQ underwritten by Piper Jaffray; JMP Securities; Cantor Fitzgerald; and Summer Street Research Partners. Virobay...
Items per page:
1 - 10 of 15
BioCentury | Jan 24, 2018
Emerging Company Profile

D over L for diabetes

...antigens in preclinical through Phase I testing for the disease. At least one other company, Virobay Inc....
...not specific for any one HLA allele, the strategy could lead to overly broad immunosuppression. Virobay...
...Mentioned ImmunoMolecular Therapeutics LLC, Broomfield, Colo. JDRF, New York, N.Y. Tolerion Inc., Portola Valley, Calif. Virobay Inc....
BioCentury | Jul 25, 2017
Distillery Therapeutics

Autoimmune disease

...with vehicle. Next steps could include identifying and testing CTSS inhibitors in models of lupus. Virobay Inc....
...in Phase I testing to treat pain and in discovery research to treat Alzheimer's disease. Virobay...
BioCentury | Aug 18, 2015
Company News

Management tracks

...Palo Alto, Calif.) named James Welch CFO and James Shaffer CBO. Welch was CFO at Virobay Inc....
BioCentury | Nov 10, 2014
Financial News

Virobay withdraws IPO

...Date announced: 2014-10-31 Type: IPO Underwriters: Piper Jaffray; JMP Securities; Cantor Fitzgerald; Summer Street Note: ViroBay...
BioCentury | Nov 1, 2014
Financial News

Virobay pulls IPO

Virobay Inc. (Menlo Park, Calif.) withdrew its proposed IPO on NASDAQ, citing market conditions. Earlier this month, the company amended its offering to sell 3.8 million shares at $12-$14. At $13, it would have raised...
BioCentury | Oct 13, 2014
Financial News

Virobay amends IPO

...IPO on NASDAQ and now plans to sell 3.8 million shares at $12-$14. In September, Virobay...
BioCentury | Oct 7, 2014
Financial News

Virobay, Xenon set IPO terms

...proposed IPOs on NASDAQ Virobay plans to sell 3.8 million shares at $12-$14. At $13, Virobay...
...$169 million. Piper Jaffray; JMP Securities; Cantor Fitzgerald; and Summer Street Research Partners are underwriters. Virobay...
BioCentury | Oct 6, 2014
Finance

4Q14 Financial Markets Preview: 'Perfect world' - for now

...9/15/14 Up to $65M Ph II Kolltan Pharmaceuticals Inc. 9/12/14 Up to $86.3M Ph I Virobay Inc....
BioCentury | Sep 15, 2014
Financial News

Virobay proposes IPO

Virobay Inc. , Menlo Park, Calif. Business: Autoimmune, Neurology, Hepatic Date announced: 2014-09-10 Type: IPO To be raised: Up to $50 million Shares: TBD Price: TBD Underwriters: Piper Jaffray; JMP Securities; Cantor Fitzgerald; Summer Street Note:...
BioCentury | Sep 12, 2014
Financial News

Virobay files for IPO

...on NASDAQ underwritten by Piper Jaffray; JMP Securities; Cantor Fitzgerald; and Summer Street Research Partners. Virobay...
Items per page:
1 - 10 of 15